Booster Dose of the Pfizer/BioNTech COVID-19 Vaccine (Comirnaty)
October 18, 2021 (Issue: 1635)
On September 22, on the advice of its Vaccines and
Related Biologic Products Advisory Committee, the
FDA expanded the Emergency Use Authorization
(EUA) for the Pfizer/BioNTech mRNA-based COVID-19
vaccine (Comirnaty) to include administration of...more
- FDA News Release. FDA authorizes booster dose of Pfizer-BioNTech COVID-19 vaccine for certain populations. September 22, 2021. Available at: https://bit.ly/3ilp0B1. Accessed September 30, 2021.
- CDC. CDC statement on ACIP booster recommendations. September 24, 2021. Available at: https://bit.ly/3o8uS42. Accessed September 30, 2021.
- FDA. Fact sheet for health care providers administering vaccine (vaccination providers). Emergency Use Authorization (EUA) of the Pfizer-BioNTech COVID-19 vaccine to prevent coronavirus disease 2019 (COVID-19). September 22, 2021. Available at: https://bit. ly/37fX1NG. Accessed September 30, 2021.
- SY Tartof et al. Six-month effectiveness of BNT162b2 mRNA COVID-19 vaccine in a large US integrated health system: a retrospective cohort study. 2021 August 23 (preprint). Available at: https://bit.ly/3CJwzJ8. Accessed September 30, 2021.
- Y Goldberg et al. Waning immunity of the BNT162b2 vaccine: a nationwide study from Israel. medRxiv 2021 August 30 (preprint). Available at: https://bit.ly/2XXy4Vr. Accessed September 30, 2021.
- YM Bar-On et al. Protection of BNT162b2 vaccine booster against Covid-19 in Israel. N Engl J Med 2021 September 15 (epub).
- AM Hause et al. Safety monitoring of an additional dose of COVID-19 Vaccine — United States, August 12–September 19, 2021. MMWR Morb Mortal Wkly Rep 2021 September 28 (epub).
- FDA. FDA review of effectiveness and safety of COMIRNATY (COVID-19 vaccine, mRNA) booster dose. Biologics License Application supplement. Vaccines and Related Biological Products Advisory Committee. September 17, 2021. Available at: https://bit.ly/2ZhqsgQ. Accessed September 30, 2021.
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.
Would you like to read the rest of this issue? Gain access below.
Subscribe
Subscriptions to
The Medical Letter on Drugs and Therapeutics include:
- Print version published and mailed biweekly (26 issues/year)
- Unlimited online access to current and past issues (1988 - present)
- Mobile App
- FREE online per issue CME/CE
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
